دورية أكاديمية
أعرض في EDS

Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine.

التفاصيل البيبلوغرافية
العنوان: Enhanced efficacy in drug-resistant cancer cells through synergistic nanoparticle mediated delivery of cisplatin and decitabine.
المؤلفون: Parhizkar M; School of Pharmacy, University College London London UK maryam.parhizkar@ucl.ac.uk.; Mechanical Engineering, University College London London UK., Reardon PJT; Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London London UK., Harker AH; Department of Physics and Astronomy, University College London London UK., Browning RJ; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford Oxford UK., Stride E; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford Oxford UK., Pedley RB; UCL Cancer Institute, Department of Oncology, University College London London UK., Knowles JC; Division of Biomaterials and Tissue Engineering, UCL Eastman Dental Institute, University College London London UK.; The Discoveries Centre for Regenerative and Precision Medicine UCL Campus London UK.; Department of Nanobiomedical Science, BK21 PLUS NBM Global Research Center for Regenerative Medicine, Dankook University Cheonan 31114 Republic of Korea.; UCL Eastman-Korea Dental Medicine Innovation Centre, Dankook University Cheonan 31114 Republic of Korea., Edirisinghe M; Mechanical Engineering, University College London London UK.
المصدر: Nanoscale advances [Nanoscale Adv] 2020 Jan 27; Vol. 2 (3), pp. 1177-1186. Date of Electronic Publication: 2020 Jan 27 (Print Publication: 2020).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Royal Society of Chemistry Country of Publication: England NLM ID: 101738708 Publication Model: eCollection Cited Medium: Internet ISSN: 2516-0230 (Electronic) Linking ISSN: 25160230 NLM ISO Abbreviation: Nanoscale Adv Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Cambridge : Royal Society of Chemistry, [2019]-
مستخلص: There are several limitations with monodrug cancer therapy, including poor bioavailability, rapid clearance and drug resistance. Combination therapy addresses these by exploiting synergism between different drugs against cancer cells. In particular, the combination of epigenetic therapies with conventional chemotherapeutic agents can improve the initial tumour response and overcome acquired drug resistance. Co-encapsulation of multiple therapeutic agents into a single polymeric nanoparticle is one of the many approaches taken to enhance therapeutic effect and improve the pharmacokinetic profile. In this study, different types of poly(lactic- co -glycolic acid) (PLGA) nanoparticles (NPs), matrix and core-shell (CS), were investigated for simultaneous encapsulation of a demethylating drug, decitabine, and a potent anticancer agent, cisplatin. It was shown that by altering the configuration of the CS structure, the release profile could be tuned. In order to investigate whether this could enhance the anticancer effect compared to cisplatin, human ovarian carcinoma cell line (A2780) and its cisplatin resistant variant (A2780cis) were exposed to free cisplatin and the CS-NPs. A better response was obtained in both cell lines (11% and 51% viability of A2780 and A2780cis, respectively) using CS-NPs than cisplatin alone (27%, 82% viability of A2780 and A2780cis, respectively) or in combination with decitabine (22%, 96% viability of A2780 and A2780cis, respectively) at equivalent doses (10 μM).
Competing Interests: There are no conflicts to declare.
(This journal is © The Royal Society of Chemistry.)
References: J Control Release. 2011 Aug 10;153(3):198-205. (PMID: 21663778)
Nanomedicine. 2016 Oct;12(7):1919-1929. (PMID: 27184098)
J Am Chem Soc. 2014 Aug 20;136(33):11748-56. (PMID: 25078892)
Int J Pharm. 2018 Apr 5;540(1-2):132-149. (PMID: 29427746)
Adv Drug Deliv Rev. 2009 Oct 5;61(12):1043-54. (PMID: 19651167)
Int J Nanomedicine. 2017 Nov 23;12:8427-8442. (PMID: 29200853)
Biomaterials. 2013 Oct;34(32):7905-12. (PMID: 23891514)
Biochem Pharmacol. 2012 Apr 15;83(8):1104-11. (PMID: 22285912)
Int J Nanomedicine. 2017 May 23;12:3913-3926. (PMID: 28579777)
Eur J Pharm Sci. 2009 Jun 28;37(3-4):300-5. (PMID: 19491019)
Trends Mol Med. 2015 Apr;21(4):223-32. (PMID: 25656384)
Nanoscale. 2017 May 11;9(18):5975-5985. (PMID: 28440835)
Br J Cancer. 2014 Jan 7;110(1):123-32. (PMID: 24178762)
Front Pharmacol. 2016 Jun 28;7:185. (PMID: 27445821)
J Am Chem Soc. 2014 Apr 23;136(16):5896-9. (PMID: 24724706)
PLoS One. 2014 Nov 12;9(11):e112880. (PMID: 25391133)
Mater Sci Eng C Mater Biol Appl. 2016 Sep 1;66:138-146. (PMID: 27207047)
ACS Nano. 2017 Sep 26;11(9):8560-8578. (PMID: 28829568)
Nano Today. 2017 Aug;15:91-106. (PMID: 29225665)
Ther Deliv. 2010 Aug;1(2):323-34. (PMID: 22816135)
Oncotarget. 2017 Jun 6;8(23):38022-38043. (PMID: 28410237)
J Aerosol Sci. 2018 Nov;125:164-181. (PMID: 30662086)
Am J Physiol Cell Physiol. 2014 Dec 15;307(12):C1071-80. (PMID: 25252947)
Ann Transl Med. 2018 Jun;6(11):229. (PMID: 30023392)
Cancer. 1975 Jan;35(1):98-110. (PMID: 162854)
Sci Rep. 2016 Feb 15;6:21225. (PMID: 26876480)
Proc Natl Acad Sci U S A. 2013 Nov 12;110(46):18638-43. (PMID: 24167294)
Chem Soc Rev. 2012 Apr 7;41(7):2971-3010. (PMID: 22388185)
Br J Cancer. 2009 Mar 10;100(5):758-63. (PMID: 19259094)
J Clin Oncol. 2006 Jun 20;24(18):2786-92. (PMID: 16782917)
Nanomedicine (Lond). 2013 May;8(5):687-98. (PMID: 23075285)
معلومات مُعتمدة: 21030 United Kingdom CRUK_ Cancer Research UK; G1001497 United Kingdom MRC_ Medical Research Council
تواريخ الأحداث: Date Created: 20220922 Latest Revision: 20240210
رمز التحديث: 20240210
مُعرف محوري في PubMed: PMC9419023
DOI: 10.1039/c9na00684b
PMID: 36133040
قاعدة البيانات: MEDLINE
الوصف
تدمد:2516-0230
DOI:10.1039/c9na00684b